Dr Georg Bach re-elected President of the DGZI

Germany's oldest implantology society

strengthens its leadership

Freiburg-based oral surgeon Dr Georg Bach has been re-elected as President of the German Association of Dental Implantology (DGZI) during the general assembly held in Hamburg on 2 October. In his initial statement, Dr Bach expressed gratitude to his fellow board members for their dedication over the past years and voiced his enthusiasm for continuing their productive collaboration.

This new term marks Dr Bach's third tenure as president of Germany's oldest professional society dedicated to implantology. His re-election not only underscores continuity in the DGZI's leadership but also signals the society's strategic vision for the future.

Looking ahead, Dr Bach aims to showcase oral implantology as an inspiring and innovative field to the next generation of dentists. He is committed to strengthening the critical interface between dentistry and dental technology, while further establishing the



DGZI as a dynamic, forward-thinking, and future-oriented professional society.

Source: German Association of Dental Implantology (DGZI)

Patent Medical

Patent Medical awarded "Dental Implants Manufacturer of the Year"



Swiss dental implant specialist Patent Medical has been named "Dental Implants Manufacturer of the Year in Europe" by MedTech Outlook. The award recognises Patent™ as the first implant system to achieve a scientifically proven bond between peri-implant soft tissue and a transmucosal implant surface—an advancement regarded as a decisive breakthrough in the field of dental implantology.

MedTech Outlook is a leading US-based trade magazine that provides in-depth coverage of advances in medical technology. The magazine honours companies developing disruptive medical technologies, and its recognition of Patent's implant system acknowledges the company's significant contribution to the prevention of peri-implantitis.

Soft-tissue bond to prevent peri-implantitis

The Patent™ Dental Implant System has demonstrated a bond between peri-implant mucosa and a synthetic surface—a first in the history of dentistry. A research team led by Prof. Anton Sculean, Dr Peter Schüpbach, Dr Roland Glauser and Prof. Dieter Bosshardt confirmed this novel cell bond in histological investigations.

Patent[™] Implants undergo a proprietary surface treatment that imparts mucophilic and cell-occlusive properties—enhancing soft-

tissue integration and creating a barrier to bacterial ingress—as well as a surface topography modelled on natural tooth structure. As a result, epithelial cells begin to grow on to the transmucosal Patent TM surface already in the early stages of healing, ultimately establishing a bond with it.

At EuroPerio11 in Vienna in Austria, where these histological results were presented during a symposium, Dr Glauser emphasised that the soft-tissue bond to the transmucosal Patent surface functions as a dynamic protective barrier that stops plaque from migrating downwards into the tissue and thereby protects it from bacterial invasion. Consequently, the risk of inflammation and tissue recession is greatly reduced, progression from mucositis to peri-implantitis is prevented, and stable aesthetics are maintained long term.

Peri-implantitis prevented in long-term studies

The efficacy of this soft-tissue bond in preventing peri-implantitis has been demonstrated in long-term studies at universities in Germany and Austria—even in high-risk patients with periodontitis or

systemic diseases such as cancer, diabetes or multiple sclerosis or in patients with poor oral hygiene or smoking habits.

Patent Medical info@mypatent.com www.mypatent.com

